- Home
- ALLR
as 06-06-2025 4:00pm EST
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
| Founded: | 2004 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 4.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 564.1K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.61 - $17.35 | Next Earning Date: | 08-04-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Allarity Therapeutics Inc. News
ALLR Breaking Stock News: Dive into ALLR Ticker-Specific Updates for Smart Investing
GlobeNewswire
3 days ago
Allarity Therapeutics Announces Research Collaboration with Indiana Biosciences Research Institute to Further Advance Understanding of Stenoparib’s Unique, Dual Therapeutic Mechanism of Action
GlobeNewswire
5 days ago
Allarity Therapeutics Announces First Patient Enrolled in New Phase 2 Clinical Trial Protocol of Stenoparib in Advanced Ovarian Cancer
GlobeNewswire
a month ago
Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
GlobeNewswire
a month ago
Allarity Therapeutics Provides First Quarter 2025 Update, Highlighting Continued Stenoparib Benefit and Upcoming Trial Enrollment
GlobeNewswire
a month ago
Allarity Therapeutics Presents Novel Drug Response Predictor—DRP®—for Daratumumab in Multiple Myeloma at AACR 2025
GlobeNewswire
2 months ago
Allarity Therapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
GlobeNewswire
2 months ago
Allarity Therapeutics Launches Comprehensive Effort to Combat Potential Illegal Naked Short Selling of Its Shares
GlobeNewswire
3 months ago
Allarity Therapeutics Announces Presentation of Phase 2 Clinical Data from Ongoing Trial in Advanced Ovarian Cancer Patients at the 2025 Annual Meeting for the Society of Gynecologic Oncology
Compare ALLR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALLR Allarity Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.